{
  "event_id": "2248935f875b",
  "ticker": "PCYC",
  "company_name": "Pharmacyclics",
  "drug_name": "IMBRUVICA",
  "pdufa_date": "20160208",
  "approval_type": {
    "status": "found",
    "value": "nda",
    "source": "websearch:PCYC-1104 Phase 2 (Accelerated Nov 2013)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.532498",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Mantle cell lymphoma",
    "source": "websearch:PCYC-1104 Phase 2 (Accelerated Nov 2013)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.532500",
    "error": null
  },
  "generic_name": {
    "status": "not_searched",
    "value": null,
    "source": null,
    "confidence": 0.0,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "_reset_reason": "Was inferred from: brand_to_generic_map",
    "_reset_at": "2026-01-09T23:49:24.204703"
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Hematology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:58.986934",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "derived_from_result",
    "confidence": 0.95,
    "tier": 1,
    "searched_sources": [
      "result_field"
    ],
    "last_searched": null,
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:PCYC-1104 Phase 2 (Accelerated Nov 2013)",
    "confidence": 0.95,
    "evidence": [
      "PCYC-1104 Phase 2 (Accelerated Nov 2013)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.532481",
    "error": null
  },
  "p_value": {
    "status": "not_applicable",
    "value": null,
    "source": "websearch:PCYC-1104 Phase 2 (Accelerated Nov 2013)",
    "confidence": 0.9,
    "evidence": [
      "Single-arm or accelerated approval - no comparator p-value"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.532490",
    "error": null
  },
  "p_value_numeric": null,
  "effect_size": {
    "status": "found",
    "value": "ORR 71%",
    "source": "websearch:PCYC-1104 Phase 2 (Accelerated Nov 2013)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.532493",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma",
    "A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"
  ],
  "nct_ids": [
    "NCT01236391",
    "NCT02264574"
  ],
  "enrollment": {
    "count": 229,
    "type": "ACTUAL",
    "nct_id": "NCT02264574",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:29:15.325503"
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:37:25.946439",
  "enriched_at": "2026-01-11T19:51:24.349623",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "43400ea8b10a",
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": true
  },
  "mechanism_of_action": "BTK inhibitor",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -3624,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:41.327596",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:43:12.670661"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:43:12.670668"
  },
  "breakthrough_therapy": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Ibrutinib (IMBRUVICA®) Granted Breakthrough Therapy ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:51:14.697521",
    "search_status": "FOUND"
  },
  "orphan_drug": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "Search Orphan Drug Designations and Approvals Ibrutinib (IMBRUVICA®) Granted Breakthrough Therapy .."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:51:15.954831",
    "search_status": "FOUND"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:51:17.202897",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:51:23.362200",
    "search_status": "CONFIRMED_NONE"
  },
  "accelerated_approval": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Imbruvica (ibrutinib) FDA Approval History - Drugs.com Update on IMBRUVICA® (ibrutinib) U.S. Acceler"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:51:24.349612",
    "search_status": "FOUND"
  }
}